Claritas Pharmaceuticals, Inc. Share Price

CLAZF

CA1806342061

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 17:16:04 27/02/2026 GMT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap	5.37M 3.8M 3.33M 3.08M 2.84M 363M 5.47M 36.77M 14.42M 178M 14.26M 13.95M 616M	P/E 2019	-0.74x	P/E 2020	0.13x
Enterprise Value	6.29M 4.45M 3.9M 3.61M 3.32M 426M 6.41M 43.07M 16.89M 209M 16.7M 16.34M 722M	EV / Sales 2019	-	EV / Sales 2020	-
Free-Float	99.74%	Yield 2019 *	-	Yield 2020	-

* Estimated data More valuation ratios

Chart: Claritas Pharmaceuticals, Inc.

Dynamic Chart

Managers and Directors: Claritas Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Farrell CEO	Chief Executive Officer	76	20/06/2017
Victoria Rudman DFI	Director of Finance/CFO	58	28/06/2018

Director	Title	Age	Since
Robert Farrell CHM	Chairman	76	17/03/2021

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CLARITAS PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	37
LONZA GROUP AG	+0.44%	+1.41%	+4.36%	+10.81%	50.73B
REVOLUTION MEDICINES, INC.	-1.57%	-3.18%	+383.82%	+593.37%	39.73B
IQVIA HOLDINGS INC.	-0.14%	+0.77%	+27.49%	-5.50%	34.69B
BEONE MEDICINES AG	+1.76%	-1.78%	+21.44%	+53.38%	33.21B
CELLTRION, INC.	-0.06%	-0.45%	+2.94%	+28.70%	26.76B
ASCENDIS PHARMA A/S	-1.93%	-1.01%	-	-	16.8B
MEDPACE HOLDINGS, INC.	-1.49%	-6.18%	+63.89%	+120.53%	15.37B
EUROFINS SCIENTIFIC SE	+0.78%	+1.16%	+14.69%	+17.32%	13.78B
ICON PUBLIC LIMITED COMPANY	-0.97%	-2.83%	+10.35%	-33.29%	12.85B
Average	-0.32%	-0.87%	+66.12%	+98.16%	24.39B
Weighted average by Cap.	-0.18%	-0.35%	+81.60%	+123.89%

See all sector performances

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâ€™s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
CLAZF Stock

Google lets you customize your preferred sources.

Choose MarketScreener

3 years	0		0
5 years	0		0.7
10 years	0		15.31

Date	Insider	Type	Quantity	% Market Cap.
10/10/21	Andrew Salzman	Buy	152,500	0.4307%
10/10/21	Andrew Salzman	Buy	24,500	0.0692%
10/10/21	Andrew Salzman	Buy	118,000	0.3332%

	2019	2020
Net sales	-	-
Net income	-21.21M -15M -13.16M -12.19M -11.21M -1.44B -21.62M -145M -56.97M -705M -56.34M -55.11M -2.44B	4.21M 2.98M 2.61M 2.42M 2.23M 285M 4.29M 28.83M 11.31M 140M 11.18M 10.94M 483M
Net Debt	704K 498K 437K 405K 372K 47.66M 718K 4.82M 1.89M 23.4M 1.87M 1.83M 80.83M	920K 651K 571K 529K 486K 62.28M 938K 6.3M 2.47M 30.59M 2.44M 2.39M 106M

Claritas Pharmaceuticals, Inc. Share Price

Stocks

CLAZF

CA1806342061

Biotechnology & Medical Research

Valuation: Claritas Pharmaceuticals, Inc.

Chart: Claritas Pharmaceuticals, Inc.

Course Extremes

Managers and Directors: Claritas Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile